Tagrisso, also known as osimertinib, is a medication used to treat certain types of non-small cell lung cancer (NSCLC) [1]. Its wholesale acquisition cost, which is the price manufacturers sell to wholesalers and distributors, varies.
What is the wholesale acquisition cost of Tagrisso?
The wholesale acquisition cost (WAC) for Tagrisso can differ based on the dosage form and quantity. For instance, a 30-count bottle of 40 mg tablets has a WAC of approximately \$20,792, while a 30-count bottle of 80 mg tablets has a WAC of approximately \$20,792 as well [2]. These prices represent the list price before any discounts or rebates [2].
Who manufactures Tagrisso and what is its patent status?
Tagrisso is manufactured by AstraZeneca [1]. Information regarding specific patent expiry dates and potential market exclusivity can be found on resources like DrugPatentWatch.com, which tracks pharmaceutical patents and their timelines [3].
What are the approved uses for Tagrisso?
Tagrisso is approved for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) – mutated NSCLC. This includes its use as a first-line treatment for patients with EGFR exon 19 deletions or EGFR exon 21 (L858R) substitution mutations [1]. It is also indicated for patients with EGFR T790M mutation-positive metastatic NSCLC whose disease has progressed on or after prior EGFR tyrosine kinase inhibitor therapy [1].
How does Tagrisso work?
Tagrisso is a third-generation, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) [1]. It targets specific mutations in the EGFR gene that drive cancer growth [1]. It is designed to be more potent against certain EGFR mutations, including the T790M resistance mutation, and to have better penetration into the central nervous system [1].
What are the potential side effects of Tagrisso?
Common side effects of Tagrisso include diarrhea, rash, dry skin, and nail problems [1]. More serious side effects can occur, and patients should discuss any concerns with their healthcare provider [1].
Are there alternative treatments for EGFR-mutated NSCLC?
Yes, there are other treatments available for EGFR-mutated NSCLC, including other EGFR TKIs. The choice of treatment depends on the specific EGFR mutation, stage of cancer, and individual patient factors [1].
Can biosimilars of Tagrisso be developed?
The development and approval of biosimilars are subject to complex patent and regulatory pathways. Generally, biosimilars can enter the market after the expiry of relevant patents and exclusivity periods [3].
Where can I find more information on Tagrisso pricing and availability?
For detailed information on drug pricing, patents, and market exclusivity, resources such as DrugPatentWatch.com can provide valuable data [3]. Information on patient assistance programs may also be available through the manufacturer or healthcare providers.
Sources:
[1] https://www.tagrisso.com/
[2] https://www.goodrx.com/tagrisso
[3] https://drugpatentwatch.com/